Doc No. SF-023	Point of Care Schemes	Version: 1
Owner: M. Forsyth	Author: M. Forsyth	Date of Issue: 28.08.19

Point of Care Scheme (Plasma)	
Number of samples (All Methods, all analytes)	Two lyophilised samples per distribution + 500 µL of diluents supplied in plastic vials for each sample.
Frequency of distribution:	Twelve per year
Range of tests:	Cardiac Troponin I, CKMB, Myoglobin, and *B-type Natriuretic Peptide* (BNP)
Concentration ranges:	Varied by analyte additions
Troponin I additions are in the form of a complex. This complex is released in to the bloodstream of patients with myocardial muscle cell injury and have the required source specificity. CKMB and Myoglobin also have required source specificity. BNP is a synthetic peptide which has the required source specificity.	
Concentration ranges employed in this EQA Scheme(cTnI, CKMB and Myoglobin)	
These cover the clinically encountered range from less than the assay detection limit, levels around the diagnostic decision limits and levels found in the 24 hours following myocardial infarction or after thrombolysis wash out The numerical values depend on the assay method.	
Concentration employed in this EQA (BNP)	
These cover the clinically encountered ranges from less than the assay detection limit, levels around the diagnostic decision limits and levels found in patients with heart failure. For BNP the numerical value is depends on the assay method.	
Base Matrix:	Pooled human EDTA Plasma (Female only)

Point of Care Scheme (Serum)	
Number of samples (All Methods, all analytes)	Two lyophilised samples per distribution + 500 µL of diluents supplied in plastic vials for each sample.
Frequency of distribution:	Twelve per year
Range of tests:	The EQA covers cardiac Troponin I, cardiac Troponin T, CKMB, Myoglobin and NT-pro *B-type natriuretic peptide* (NT-proBNP)
Concentration ranges:	Varied by analyte additions
Troponin I and T additions are in the form of a complex. This complex is released in to the bloodstream of patients with myocardial muscle cell injury and has the required source specificity. CKMB and Myoglobin also have required source specificity NT-ProBNP is a recombinant peptide which has the required source specificity.	
Concentration ranges employed in this EQA Scheme(cTnI, cTnT, CKMB and Myoglobin)	
These cover the clinically encountered range from less than the assay detection limit, levels around the diagnostic decision limits and levels found in the 24 hours following myocardial infarction or after thrombolysis wash out The numerical values depend on the assay method.	
Concentration employed in this EQA (NT-proBNP)	
These cover the clinically encountered ranges from less than the assay detection limit, levels around the diagnostic cut-off and levels found in patients with heart failure. For NT-proBNP the numerical value depends on the assay method.	
Base Matrix:	Pooled human Serum (Female only)